Evommune Cash Flow Statement (2024-2026) | EVMN

Cash Flow Statement Sep2024 Dec2024 Mar2025 Sep2025 Dec2025 Mar2026
Operating Activities
Net Income (Quarter) -15.92M-20.16M-14.62M-19.37M-27.88M-113.64M
Share-based Compensation (Quarter) 0.40M5.50M0.56M1.10M35.90M
Cash from Operations (Quarter) -18.51M-23.90M-16.70M-27.50M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles (Quarter) 0.45M0.42M0.58M0.79M
Depreciation & Amortization (CF) (Quarter) 0.36M0.38M0.33M0.35M
Change in Working Capital
Change in Account Payables (Quarter) 2.85M-0.69M3.85M-3.75M
Change in Accured Expenses (Quarter) -0.14M-2.10M4.30M-4.81M
Other Working Capital Changes (Quarter) 0.71M3.96M0.37M0.09M
Investing Activities
Capital Expenditures (Quarter) -0.10M0.04M
Change in Acquisitions & Divestments (Quarter) 11.50M13.50M37.60M23.50M
Cash from Investing Activities (Quarter) -33.08M13.50M-122.90M-85.36M
Financing Activities
Other financing activities (Quarter) 0.01M157.28M
Cash from Financing Activities (Quarter) 49.70M-0.15M156.85M117.11M
Additional items
Change in Cash (Quarter) -1.89M-10.55M17.25M4.25M
Free Cash Flow (Quarter) -18.51M-23.90M-16.60M-27.54M
Net Cash Flow (Quarter) -1.89M-10.55M17.25M4.25M